5 reports

MARKET ##.

  • Biological Therapy
  • Interleukin
  • APAC
  • World
  • Company Sales
  • JAN 09, 2014: NEUMEDICINES TO FEATURE HEMAMAX STUDY RESULTS IN PRESENTATION AT BIOTECH SHOWCASE CONFERENCE
  • interactions involving dendritic cells, osteoblasts, and soluble factors such as IL-12 and cytoprotectant erythropoietin.

In the same study, ## consecutive days of treatment with Neupogen® (filgrastim or granulocyte colonystimulating factor [G-CSF]) did not provide any survival benefit versus control.

  • Interleukin
  • Therapy
  • United States
  • Product Initiative
  • Neumedicines Inc.
  • Pipeline by Amgen Inc., H1 2016

The molecules developed by Companies in Phase II, Phase I and Preclinical stages are ##, ## and ## respectively.

  • Interleukin
  • Monoclonal Antibody
  • Turkey
  • World
  • Product Initiative

(Stage ##) and s. c.

  • Autoimmune Disease
  • Clinical Trial
  • Interleukin
  • Pharmaceutical
  • World

THE COMPANY HAS A PIPELINE OF AN ANTI-PROGRAMMED CELL DEATH PROTEIN ## (PD-##) CHECKPOINT INHIBITOR AND OTHER THERAPEUTIC CYTOKINES.

  • Cytokine
  • Interleukin
  • Turkey
  • United States
  • Product Initiative